AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

IDYA · NASDAQ · Biotechnology

IDEAYA Biosciences (IDYA)

Develops biomarker-selected cancer drugs across small molecules and antibody-drug conjugates.

$39.71

After hours+0.01 (+0.04%)

At close$39.70(+2.15%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	8	4	0	0	0	7	0	0	208	11	7	9
Cost of revenue	1	1	1	1	1	1	71	74	83	87	96	0
Gross profit	7	3	−1	−1	−1	6	−71	−74	125	−76	−89	9
	41	45	50	64	66	150	14	15	16	19	19	131
Research & development	34	39	43	55	57	140	71	74	83	87	96	109
	7	6	7	9	9	10	14	15	16	19	19	22
General & administrative	0	0	0	0	0	0	14	15	16	19	19	22
Other expenses	0	0	0	0	0	0	−71	−74	−83	−87	−96	0
Operating income	−34	−42	−51	−65	−67	−144	−84	−89	108	−95	−109	−122
	6	8	11	12	15	14	12	11	11	11	10	10
Interest income	6	8	11	12	15	14	12	11	11	11	10	10
Other non-operating income	−6	−8	−11	−12	−15	−14	0	0	0	0	0	0
Income before tax	−27	−34	−40	−53	−52	−130	−72	−77	119	−83	−99	−112
Net income from continuing operations	−27	−34	−40	−53	−52	−130	−72	−77	119	−83	−99	−112
Net income	−27	−34	−40	−53	−52	−130	−72	−77	119	−83	−99	−112
EPS, basic	−$0.46	−$0.52	−$0.53	−$0.68	−$0.60	−$1.49	−$0.82	−$0.88	$1.35	−$0.94	−$1.11	−$1.22
EPS, diluted	−$0.46	−$0.52	−$0.53	−$0.68	−$0.60	−$1.49	−$0.82	−$0.88	$1.33	−$0.94	−$1.11	−$1.22
Weighted average shares, basic	60	65	75	78	86	87	88	88	90	89	89	92
Weighted average shares, diluted	60	65	75	78	86	87	88	88	90	89	89	92
EBITDA	−26	−33	−38	−52	−51	−130	−83	−88	109	−93	−107	−121
Depreciation & amortization	1	1	1	1	1	1	1	1	1	1	1	1
EBIT	−27	−34	−40	−53	−52	−130	−84	−89	108	−95	−109	−122